Tag Archive for: Medtech

Zephyrus Innovations appoints David Whitaker as Chief Technology Officer

Vancouver, Canada – 30 May 2023: Zephyrus Innovations (Zephyrus), a privately-owned medical device company designing and manufacturing safety syringes and Closed System Transfer Devices (CSTDs), today announces the appointment of David Whitaker as Chief Technology Officer. David brings with him more than 20 years’ experience in the development and manufacture of medical devices. Until recently, […]

AMSilk Announces Extension of Series C Financing to EUR 54M

Funding enables AMSilk to accelerate industrial scale-up and expand commercial operations of bio-fabricated silk protein materials Financing led by existing investors ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. Munich, 4. April, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised […]

Zephyrus Innovations announces US FDA approval for its Aeroject™ 3ml safety syringe

Aeroject™ 3ml safety syringe is a single-use, affordable, first generation syringe Aeroject™ has a permanently attached needle system, which upon retraction, fully encases the needle, preventing needle reuse and accidental needlestick The ultra-low wasted space syringes allow for the maximum number of doses to be administered per vial, lowering costs 16 February 2023 – Vancouver, Canada: […]

Optimum Expands its Team with Senior Investor Relations and Communications Hires Jonathan Edwards and Hana Malik

14 February 2023 – Optimum Strategic Communications (“Optimum”), the specialist life sciences communications consultancy, today announces that it has hired Jonathan Edwards and Hana Malik, two highly experienced investor relations and communications professionals, to join as permanent members of its team. Edwards and Malik have joined Optimum as Account Directors and will be advising clients across […]

Sequana Medical announces 2022 Full Year Results and 2023 Outlook

alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total cash position of €18.9 million at end 2022 and cash runway […]